Trial intelligence / Profile preview

ALBATROS phase II lorlatinib after first-line ROS1 TKI failure in advanced ROS1-positive NSCLC

2020-004466-19Phase 2Active

Sponsor

IFCT

Start

Oct 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1